| Name | Title | Contact Details |
|---|
As the drug development business of Laboratory Corporation of America Holdings (LabCorp) and the world’s most comprehensive drug development service company, we have helped pharmaceutical and biotech companies develop 100% of the top 50 prescription drugs in the marketplace today. Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality.
Accelerating progress and time to market of biopharmaceuticals with our integrated CDMO and Testing Service Platform. Global HQ in Philadelphia, PA.
Aurora Spine Corporation focuses on the development and distribution of spinal implant products for relieving back pain, and preserving spinal bone structure and anatomy in the United States. The company intends to provide interspinous process lumbar fusion devices for patients suffering from degenerative disc disease whose pain has not been eliminated by non-surgical treatment methods; polyether ether ketone interbody cages for use in spinal fusion procedures; and cervical and lumbar devices. It also plans to develop installation tools for surgeons. The company was incorporated in 2013 and is headquartered in Toronto, Canada.
Miller Medical Specialties Inc is a Jenison, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.